LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
| Autor: | Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Ozguroglu, M., Ji, J.H., Voitko, O., Poltoratskiy, A., Verderame, F., Havel, L., Bondarenko, I., Losonczy, G., Conev, N.V., Broadhurst, H.L., Dalvi, T., Jiang, H., Goldman, J.W. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S1338-S1338 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|